Evidence for a Distinct Ca2+ Antagonist Receptor for the Novel Benzothiazinone Compound HOE 166

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1988 Mar 1

PMID 2839780

Citations 1

Authors

J Striessnig

E Meusburger

M Grabner

H G Knaus

H Glossmann

J Kaiser

B Scholkens

R Becker

W Linz

R Henning

Affiliations

Soon will be listed here.

Abstract

The pharmacological and binding properties of the novel enantiomerically pure benzothiazinone (R)-(+)-3,4-dihydro-2-isopropyl-4-methyl-2-[2-[4-[4-[2-(3,4,5-tri- methoxyphenyl)-ethyl]-piperazinyl]-butoxyl-phenyl]-2H-1,4- benzothiazine-3-one dihydrochloride (HOE 166), are described. HOE 166 stereoselectively inhibited KCl-but not noradrenaline-induced contractions of guinea-pig pulmonary arteries, rabbit aorta, rat mesenteric artery preparations and k-strophantin-induced enhancement of guinea-pig papillary muscle contraction in a dose-dependent manner. KCl-induced smooth muscle contraction was inhibited by HOE 166 with IC50-values of approximately 70 nM (5-11 times less potent than nifedipine, 2-16 times more potent than verapamil), the respective S-(-)-enantiomer being approximately 10-fold less potent. HOE 166 decreased the upstroke velocity of the slow action potential in partially depolarized guinea-pig papillary muscle at similar concentrations than nifedipine. To investigate possible interactions with the calcium channel, HOE 166 and its S-(-)-enantiomer were characterized by radioligand binding studies in heart, brain and skeletal muscle transverse-tubule membranes. HOE 166 was a 4-15 times more potent inhibitor of reversible (+)-[3H]PN200-110, (-)-[3H]desmethoxyverapamil and d-cis [3H]diltiazem binding compared to its pharmacologically less active (S)-(-)-enantiomer, with IC50 values in the low nanomolar range. Extensive equilibrium and kinetic studies suggest that HOE 166 exerts its Ca2+-antagonistic effect by binding to a Ca2+-channel-associated drug receptor which is distinct from the 1,4-dihydropyridine, phenylalkylamine or benzothiazepine-selective domain. This HOE 166-selective site is, however, allosterically linked to the other sites of the Ca2+ antagonist receptor complex. We conclude that HOE 166 is a novel calcium antagonist.

Citing Articles

[3H]HOE166 defines a novel calcium antagonist drug receptor--distinct from the 1,4 dihydropyridine binding domain.

Grassegger A, Striessnig J, Weiler M, Knaus H, Glossmann H Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(6 Pt 2):752-9.

PMID: 2561307 DOI: 10.1007/BF00169685.

References

Lindner E, Ruppert D . Effects of calcium antagonists on coronary spasm and pulmonary artery contraction in comparison to their antagonistic action against K-strophanthin in isolated guinea pig atria. Pharmacology. 1982; 24(5):294-302. DOI: 10.1159/000137610. View

Miller R . Multiple calcium channels and neuronal function. Science. 1987; 235(4784):46-52. DOI: 10.1126/science.2432656. View

Ferry D, Goll A, Glossmann H . Photoaffinity labelling of the cardiac calcium channel. (-)-[3H]azidopine labels a 165 kDa polypeptide, and evidence against a [3H]-1,4-dihydropyridine-isothiocyanate being a calcium-channel-specific affinity ligand. Biochem J. 1987; 243(1):127-35. PMC: 1147823. DOI: 10.1042/bj2430127. View

Romey G, Quast U, Pauron D, Frelin C, Renaud J, Lazdunski M . Na+ channels as sites of action of the cardioactive agent DPI 201-106 with agonist and antagonist enantiomers. Proc Natl Acad Sci U S A. 1987; 84(3):896-900. PMC: 304323. DOI: 10.1073/pnas.84.3.896. View

Hirasawa K, NISHIZUKA Y . Phosphatidylinositol turnover in receptor mechanism and signal transduction. Annu Rev Pharmacol Toxicol. 1985; 25:147-70. DOI: 10.1146/annurev.pa.25.040185.001051. View

KOHLHARDT M, FLECKENSTEIN A . Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1977; 298(3):267-72. DOI: 10.1007/BF00500899. View

Goll A, Ferry D, Glossmann H . Target size analysis and molecular properties of Ca2+ channels labelled with [3H]verapamil. Eur J Biochem. 1984; 141(1):177-86. DOI: 10.1111/j.1432-1033.1984.tb08172.x. View

Striessnig J, Knaus H, Grabner M, Moosburger K, Seitz W, LIETZ H . Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel. FEBS Lett. 1987; 212(2):247-53. DOI: 10.1016/0014-5793(87)81354-6. View

Garcia M, King V, Siegl P, Reuben J, Kaczorowski G . Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors. J Biol Chem. 1986; 261(18):8146-57. View

10.

Striessnig J, Knaus H, Glossmann H . Photoaffinity-labelling of the calcium-channel-associated 1,4-dihydropyridine and phenylalkylamine receptor in guinea-pig hippocampus. A 195 kDa polypeptide carries both drug receptors and has similarities to the alpha 1 subunit of the purified.... Biochem J. 1988; 253(1):39-47. PMC: 1149255. DOI: 10.1042/bj2530039. View

11.

Ruth P, Flockerzi V, von Nettelbladt E, Oeken J, Hofmann F . Characterization of the binding sites for nimodipine and (-)-desmethoxyverapamil in bovine cardiac sarcolemma. Eur J Biochem. 1985; 150(2):313-22. DOI: 10.1111/j.1432-1033.1985.tb09023.x. View

12.

Vaghy P, Williams J, Schwartz A . Receptor pharmacology of calcium entry blocking agents. Am J Cardiol. 1987; 59(2):9A-17A. DOI: 10.1016/0002-9149(87)90170-6. View

13.

Bolger G, Gengo P, Klockowski R, Luchowski E, Siegel H, Janis R . Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle. J Pharmacol Exp Ther. 1983; 225(2):291-309. View

14.

Vaghy P, Striessnig J, Miwa K, Knaus H, Itagaki K, McKenna E . Identification of a novel 1,4-dihydropyridine- and phenylalkylamine-binding polypeptide in calcium channel preparations. J Biol Chem. 1987; 262(29):14337-42. View

15.

Glossmann H, Ferry D . Assay for calcium channels. Methods Enzymol. 1985; 109:513-50. DOI: 10.1016/0076-6879(85)09112-1. View

16.

Ferry D, Glossmann H . Identification of putative calcium channels in skeletal muscle microsomes. FEBS Lett. 1982; 148(2):331-7. DOI: 10.1016/0014-5793(82)80835-1. View

17.

Postma S, Catterall W . Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by local anesthetics. Mol Pharmacol. 1984; 25(2):219-27. View

18.

Reynolds I, Snowman A, Snyder S . (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines. J Pharmacol Exp Ther. 1986; 237(3):731-8. View

19.

Striessnig J, Zernig G, Glossmann H . Human red-blood-cell Ca2+-antagonist binding sites. Evidence for an unusual receptor coupled to the nucleoside transporter. Eur J Biochem. 1985; 150(1):67-77. DOI: 10.1111/j.1432-1033.1985.tb08989.x. View

20.

Galizzi J, Borsotto M, Barhanin J, Fosset M, Lazdunski M . Characterization and photoaffinity labeling of receptor sites for the Ca2+ channel inhibitors d-cis-diltiazem, (+/-)-bepridil, desmethoxyverapamil, and (+)-PN 200-110 in skeletal muscle transverse tubule membranes. J Biol Chem. 1986; 261(3):1393-7. View